The short answer
There is no national shortage of Ozempic, Wegovy, Mounjaro or Zepbound right now. The FDA declared the tirzepatide shortage resolved in October 2024, confirmed in December 2024, and the semaglutide shortage resolved in February 2025. A pharmacy that is out is usually a short, local gap. Ask the pharmacy when stock is due or to transfer the prescription, call your prescriber if you will miss a dose, and never fill the gap with pens or vials from unverified websites.
At GLP-1 SOS we still get this message every few weeks, usually on a Friday: the pharmacy says my dose is not in, and my shot is Sunday. It feels like 2023, when these drugs were on the national shortage list. They are not anymore. What you most likely face is a local stock gap, with a short list of fixes.
At a glance
Three facts that change the plan
1
No national shortage
As of October 2026, the FDA lists semaglutide and tirzepatide injections as resolved, not in shortage.
2
Local gaps still happen
The FDA itself says patients may still see short, local disruptions as stock moves from maker to pharmacy.
3
The shortage window has closed
The temporary allowance for compounded copies tied to the shortage ended in 2025.
What actually happened to the shortage
Semaglutide injections went onto the FDA shortage list in March 2022 for Wegovy and August 2022 for Ozempic. Tirzepatide injections followed on December 15, 2022. The FDA removed tirzepatide on October 2, 2024, re-examined that decision after a lawsuit, and confirmed it on December 19, 2024. It declared the semaglutide shortage resolved on February 21, 2025, after reviewing Novo Nordisk’s supply, inventory and demand data.
Resolved has a precise meaning: the FDA’s Drug Shortages Staff finds the national market is covered, based on information from all manufacturers. It does not promise your pharmacy has your strength this week. In its tirzepatide decision the FDA wrote that patients may still see intermittent, localized supply disruptions as products move through the supply chain, and its shortage page says an out-of-stock drug is usually a temporary, local issue.
Lab note
A national shortage is a policy fact. An empty shelf is a phone-call problem.
The end of the shortage also ended a compounding window. While a drug is on the list, pharmacies may make copies of it. After each resolution, the FDA gave compounders a wind-down period: for tirzepatide, until February 18, 2025 for state-licensed pharmacies and March 19, 2025 for outsourcing facilities; for semaglutide, until April 22 and May 22, 2025. Our page on whether side effects differ on compounded GLP-1s covers what that means if you use one.
From the FDA
The dates that matter
Oct 2, 2024
tirzepatide (Mounjaro, Zepbound) shortage resolved, confirmed on reevaluation December 19, 2024
Feb 21, 2025
semaglutide (Ozempic, Wegovy) injection shortage declared resolved by FDA order
990
adverse event reports for compounded semaglutide received by the FDA as of May 31, 2026, plus more than 730 for compounded tirzepatide
Sources: FDA Drug Shortages Database; FDA decision memorandum, December 2024; FDA declaratory order, February 2025; FDA, Concerns with Unapproved GLP-1 Drugs, October 2026.
What to do
- Ask the pharmacy two questions. When is my strength due in, and can another location of the same chain fill it today? The FDA notes that most out-of-stock situations are temporary and local, with more product on the way.
- Call around, then transfer. Phone two or three nearby pharmacies with your exact drug, strength and pack. If one has it, ask it to transfer the prescription. Mail-order and the manufacturers’ own direct programs are other routes; our page on GLP-1 savings cards and manufacturer programs covers the cost side.
- Call your prescriber before the shot is late. Only your prescriber can change the strength, the pack or the plan. Each label has a rule for a late dose: Zepbound can be taken within 4 days, and for Wegovy it depends on how close the next dose is. See missed a GLP-1 dose: what to do.
- If you miss two weeks or more, do not restart at full dose alone. The Wegovy label says that after 2 or more missed doses in a row, the dose escalation is restarted at a lower dose to reduce stomach side effects. Ask your prescriber which dose to restart on.
- Never fill the gap from an unverified website. The FDA warns of counterfeit Ozempic in the US and of illegal online sellers whose products may hold the wrong ingredient, too much, too little or none. Research-only products are not medicine.
- If you use a compounded version, check the basics. A prescription, a state-licensed pharmacy named on the label, cold packing on arrival and clear dosing instructions. The FDA advises against using an injectable GLP-1 that arrives warm.
- Report a real shortage. If no pharmacy near you can get your drug for weeks, tell the FDA through its public shortage-reporting portal; it uses those reports to check supply with manufacturers.
From our support desk at GLP-1 SOS
If you wrote to us tonight about this, here is what we would say.
First, breathe: a pharmacy being out is usually a short, local gap. Call two more pharmacies tomorrow, then your prescriber, and do not buy pens or vials from any site that skips the prescription. If your shot ends up a few days late, the first injection back can bring the queasy, slow days of a dose step. We built GLP-1 SOS Daily Gut Relief for that stretch: 2 capsules with dinner, with ginger and peppermint for digestive comfort and magnesium to support regular bowel movements. It does nothing to replace your medication, and a cup of ginger tea after dinner does part of the same job.*
We answer real questions from real people every day. Write to us if yours is not here.
*GLP-1 SOS Daily Gut Relief supports regular bowel movements and digestive comfort. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
Two kinds of fix
Safe ways to bridge, and ones to skip
Safe bridges
- Another pharmacy nearby or in the same chain
- A transfer of your prescription
- A different strength or pack, if your prescriber writes it
- A licensed pharmacy that requires your prescription
Skip these
- Websites that sell without a prescription
- Products labeled for research or not for human use
- Prices that look too good to be true
- Pens or vials that look different or arrive warm
The FDA says to buy only from state-licensed pharmacies.
When to call your doctor
Call your prescriber the same day if:
- You will miss your dose and do not know the label’s rule for your drug
- You have missed two or more weekly doses in a row and need a restart plan
- A pen or vial looks different, has a different label, or arrived warm or damaged
- You used a product you now suspect is counterfeit, and feel unwell
- You have vomiting, cannot keep liquids down, or severe belly pain that does not go away after restarting
- You take insulin or a sulfonylurea and your sugars change while doses are missed or restarted
A gap of a few days is a nuisance. A medicine from an unknown source is a risk.
From the people behind the Lab
You do not have to figure this out alone.
GLP-1 SOS is the daily companion made for life on a GLP-1. Plain answers like this one, a support team that replies to real questions from real people, and daily formulas like GLP-1 SOS Daily Gut Relief, designed around the side effects that come with the medication. The GLP-1 Lab is our free education arm: no login, no paywall, no hype. Side effects are part of the road. Suffering through them is not.
Questions people also ask
Is there still an Ozempic or Wegovy shortage in 2026?
No. The FDA declared the semaglutide injection shortage resolved on February 21, 2025, and as of October 2026 its database lists it as resolved. Local pharmacies can still run out of a strength for a few days as stock moves through the supply chain, which the FDA itself acknowledges. Ask when your strength is due, or call another pharmacy.
Is there a Mounjaro or Zepbound shortage right now?
No. The FDA removed tirzepatide injections from its shortage list on October 2, 2024, and confirmed that decision on December 19, 2024, after reviewing Eli Lilly’s supply and demand data. A pharmacy may still be briefly out of one strength. Calling nearby pharmacies, asking for a transfer, or asking your prescriber about another pack size usually solves it.
Can I still get compounded semaglutide or tirzepatide now that the shortage is over?
The temporary allowance tied to the shortage ended in 2025, with final dates of March 19, 2025 for tirzepatide and May 22, 2025 for semaglutide at outsourcing facilities. The FDA says compounded drugs are not FDA approved and should be used only when a patient’s medical need cannot be met by an approved drug. Ask your prescriber what applies to you.
What happens if I miss my GLP-1 shot because the pharmacy is out?
It depends on the drug, so check your label or ask your pharmacist. The Zepbound label allows a missed dose within 4 days; after that, skip it and resume on your usual day. The Wegovy label says to take a single missed dose if the next one is more than 2 days away, and to restart the escalation lower if 2 or more doses in a row are missed. Call your prescriber before restarting.
Is it safe to buy Ozempic online without a prescription?
No. The FDA warns of counterfeit Ozempic in the US and of illegal online sellers whose products may contain the wrong ingredient, too much, too little or none. It also warns against products labeled for research or not for human consumption. Buy only from a state-licensed pharmacy with a valid prescription; the FDA’s BeSafeRx program explains how to check.
Sources (7)
- FDA Drug Shortages Database: current and resolved drug shortages. U.S. Food and Drug Administration, accessed October 2026.
- Drug Shortages. U.S. Food and Drug Administration, content current as of July 2026.
- Declaratory Order: Resolution of Shortages of Semaglutide Injection Products (Ozempic and Wegovy). U.S. Food and Drug Administration, February 21, 2025.
- Resolution of Tirzepatide Injection Product Shortage and Supply Status, decision memorandum. U.S. Food and Drug Administration, December 19, 2024.
- FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. U.S. Food and Drug Administration, content current as of October 2026.
- Wegovy (semaglutide) injection and tablets, Prescribing Information. Novo Nordisk / FDA, revised June 2026.
- Zepbound (tirzepatide) injection, Prescribing Information. Eli Lilly, revised August 2026.
Reviewed by the GLP-1 SOS editorial team · Education, not medical advice · Talk to your prescriber about your dose and your symptoms.
